Berenberg Bank set a €85.00 ($100.00) target price on MorphoSys AG (ETR:MOR) in a research report released on Thursday, October 19th. The firm currently has a buy rating on the stock.
A number of other analysts have also issued reports on MOR. Independent Research GmbH set a €84.00 ($98.82) price objective on MorphoSys AG and gave the stock a buy rating in a report on Wednesday, October 4th. Deutsche Bank AG set a €90.00 ($105.88) target price on shares of MorphoSys AG and gave the stock a buy rating in a research report on Monday, August 7th. Goldman Sachs Group, Inc. (The) set a €55.00 ($64.71) target price on shares of MorphoSys AG and gave the stock a neutral rating in a research report on Friday, August 4th. Oddo Bhf set a €81.00 ($95.29) target price on shares of MorphoSys AG and gave the stock a buy rating in a research report on Monday, September 25th. Finally, Commerzbank Ag set a €76.00 ($89.41) target price on shares of MorphoSys AG and gave the stock a buy rating in a research report on Wednesday, September 27th. Two equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. The company has an average rating of Buy and an average price target of €79.00 ($92.94).
Shares of MorphoSys AG (ETR:MOR) opened at 74.80 on Thursday. The company has a 50-day moving average price of €71.40 and a 200-day moving average price of €62.93. The stock’s market cap is €2.17 billion. MorphoSys AG has a 12 month low of €37.50 and a 12 month high of €80.67.
ILLEGAL ACTIVITY WARNING: “MorphoSys AG (ETR:MOR) PT Set at €85.00 by Berenberg Bank” was originally posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this piece of content on another website, it was illegally stolen and reposted in violation of US and international trademark & copyright legislation. The original version of this piece of content can be read at https://www.dispatchtribunal.com/2017/10/28/morphosys-ag-mor-pt-set-at-85-00-by-berenberg-bank.html.
MorphoSys AG Company Profile
MorphoSys AG, together with its subsidiaries, engages in the research, development, and optimization of therapeutic antibody drug candidates in partnerships with pharmaceutical and biotechnology companies. The company, together with its pharmaceutical partners, develops a therapeutic pipeline of approximately 100 human antibody drug candidates for the treatment of cancer, rheumatoid arthritis, Alzheimer's disease, infectious diseases, cardiovascular dysfunction, and inflammation.
Receive News & Ratings for MorphoSys AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MorphoSys AG and related companies with MarketBeat.com's FREE daily email newsletter.